Sino Biopharm/F-Star Therapeutics: U.S., UK Coordinate National Security Reviews of Controversial Deal

Published on Oct 12, 2022

The Committee on Foreign Investment in the United States (CFIUS) and the UK’s Department of Business, Energy and Industrial Strategy (BEIS) are coordinating their national security reviews of the proposed purchase of Britain-based F-Star Therapeutics (FSTX), a company linked to research of monoclonal antibodies’ use as a Covid-19 treatment, by a Sino Biopharmaceutical (HK:1177) subsidiary, […]

Already have an account? Log in.

Get unlimited access to all the journalism we offer.

© 2022 the Capitol Forum